GlaxoSmithKline "deliberately" discontinued a widely-used asthma medication in order to reap profits and families suffered, ...

CFRA analyst Wan Nurhayati revised the price target for GlaxoSmithKline (NYSE:GSK) shares, reducing it to $40.00 from the ...

Arizona Attorney General Kris Mayes on Thursday sued pharmaceutical manufacturer GlaxoSmithKline for engaging in deceptive and unfair practices ...

In a report released on February 5, David Evans from Kepler Capital maintained a Hold rating on GlaxoSmithKline (GSK – Research Report), with ...

The lawsuit filed in Maricopa County Superior Court contends GlaxoSmithKline's actions violate the Arizona Consumer Fraud Act ...

The attorney general is accusing GlaxoSmithKline of allegedly violating the Arizona Consumer Fraud Act. PHOENIX — Arizona ...

The state’s top lawyer accused a British multinational drug company of “deceptive and unfair practices” that endangered lives and exploited American taxpayers.

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £15.80. The company’s ...

Ms. Mayes is seeking a declaration that the company violated the Arizona Consumer Fraud Act, which prohibits companies from selling a new drug at artificially inflated prices, and maximum statutory ...

Spandana Sphoorty Financial Ltd, Reliance Power Ltd, Fusion Finance Ltd and Aarti Pharmalabs Ltd are among the other gainers in the BSE's 'A' group today, 06 February 2025.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...